Founded by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is usefully understood as a discovery and development stage specialty pharmaceutical company structured around improving the outcomes of cancer patients treated with radiation therapy (RT). Though RT is a proven modality for treating cancers, by developing radiation sensitizers, for Shuttle's management the mission is to improve the lives of cancer patients by developing therapies designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. The objective is to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy.
